MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural ...

Pre-wired ability in ‘resting’ T cells to remember past viral foes discovered, a promising breakthrough for targeted cancer therapies. A team of immunologists at the University of Massachusetts ...

MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat ...

LA JOLLA (February 4, 2026)—A multi-institutional study led by researchers at the Salk Institute for Biological Studies, UNC Lineberger Comprehensive Cancer Center, and UC San Diego has uncovered new ...

The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved ...

A team of immunologists at the University of Massachusetts Amherst has turned what we know about T-cells, one of the most important parts of the body's immune system, on its head, opening the door to ...